European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 23 · Tue 17 Nov 

Assets

psilocybin with trazodone (investigator-led; PEX010 25 mg and Trittico)

University of Chieti-Pescara

Molecule class
psilocybin
Phase
Phase 2a authorised
Indication
treatment-resistant depression
Sponsor geography
IT
Next catalyst
None recorded.
IP status
not_applicable

euclinicaltrials.euregistryverified 2026-09-08

Registered trials

In the briefing

Issues tagged CHIETI, the owner of this asset.

Record history